B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 166.05 DKK -0.78% Market Closed
Market Cap: 13.1B DKK

Relative Value

The Relative Value of one BAVA stock under the Base Case scenario is 225.86 DKK. Compared to the current market price of 166.05 DKK, Bavarian Nordic A/S is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAVA Relative Value
Base Case
225.86 DKK
Undervaluation 26%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
84
vs Industry
79
Median 3Y
2.8
Median 5Y
5.9
Industry
7.3
Forward
2.3
vs History
47
vs Industry
9
Median 3Y
11.4
Median 5Y
11.4
Industry
21.6
Forward
15.7
vs History
52
vs Industry
12
Median 3Y
8.2
Median 5Y
9.6
Industry
19.8
vs History
7
vs Industry
8
Median 3Y
-8.1
Median 5Y
-8.7
Industry
24.9
vs History
87
vs Industry
53
Median 3Y
1.5
Median 5Y
1.9
Industry
2.4
vs History
87
vs Industry
70
Median 3Y
2.6
Median 5Y
5.5
Industry
7.4
Forward
2
vs History
79
vs Industry
64
Median 3Y
4.7
Median 5Y
16.4
Industry
9.3
vs History
57
vs Industry
11
Median 3Y
6.6
Median 5Y
7.8
Industry
3.9
Forward
7.2
vs History
42
vs Industry
8
Median 3Y
8.4
Median 5Y
8.4
Industry
3.7
Forward
12.2
vs History
52
vs Industry
13
Median 3Y
7.1
Median 5Y
8.4
Industry
4.9
vs History
12
vs Industry
8
Median 3Y
-8.6
Median 5Y
-10.4
Industry
3.2
vs History
87
vs Industry
56
Median 3Y
1.2
Median 5Y
1.6
Industry
4.3

Multiples Across Competitors

BAVA Competitors Multiples
Bavarian Nordic A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
13B DKK 2.1 11.6 6.4 9.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 460 420.5 -173 291 -210 430.4 -208 029.2
US
Abbvie Inc
NYSE:ABBV
379.4B USD 6.7 89.5 17.4 26.3
US
Amgen Inc
NASDAQ:AMGN
170.2B USD 5.1 41.6 16.7 29.6
US
Gilead Sciences Inc
NASDAQ:GILD
140B USD 4.9 291.7 11.4 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
132.4B USD 12 -247.1 27.1 28.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 932.2 -493 -536.9 -522.6
AU
CSL Ltd
ASX:CSL
120B AUD 5 27.6 17.1 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.4B USD 5.2 16.9 11.2 12.5
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -57.1 -61.4 -55.4
NL
argenx SE
XBRU:ARGX
32.9B EUR 16.4 43 317.6 -2 339.9
P/S Multiple
Revenue Growth P/S to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/S: 3 314 766.3
2.1
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
36 460 420.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
12
10%
1.2
US
E
Epizyme Inc
F:EPE
1 932.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.2
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
16.4
37%
0.4
P/E Multiple
Earnings Growth PEG
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/E: 74.6
11.6
-15%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 291 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.5
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.6
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
291.7
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -247.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493 N/A N/A
AU
CSL Ltd
ASX:CSL
27.6
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.1 N/A N/A
NL
argenx SE
XBRU:ARGX
43
19%
2.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 53.1
6.4
-16%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 430.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.4
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.7
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.1
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
NL
argenx SE
XBRU:ARGX
317.6
168%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 20.3
9.8
-18%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 029.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26.3
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.6
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.4
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -522.6 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 339.9 N/A N/A